投資
4投資退出
1想告知投資者類似寒武紀生物製藥關於你的公司嗎?
提交你的分析師簡報在投資者麵前,CB Insights的平台上的客戶和合作夥伴。188bet游戏
最新的寒武紀生物製藥新聞
2023年5月15日
TechCrunch生活有一些驚人的顯示在過去的幾個月裏。我知道很難跟上。每個星期三,在舊PDT,生活事件功能麵臨的創始人和投資者討論大問題現在他們的行業。麵試是由頂級TechCrunch編輯(和我)。如果你不能做現場表演,他們可以在YouTube上觀看這裏的播客嵌入。身份和識別很多今天的麵試是由全球總編輯TechCrunch,英格裏德Lunden。英格麗德向裏克歌,創始人之一的角色,構建和提供了一個大型的身份驗證解決方案套件解決日益增長的身份欺詐的問題。加入裏克Index Ventures馬克·戈德堡是一個公司,做了一個有先見之明的早期發現和形象。馬克和瑞克向我們談到:角色如何保持跟上AI驗證和在線信任指數企業是如何騎在啟動經濟增長的潮流和獨特而複雜的問題,公眾的頭腦與AI寒武紀生物製藥是如何改造藥物和製藥公司開發馬特•伯恩斯向詹姆斯集合淋巴結寒武紀生物製藥的創始人之一,和Maryanna Saenko,未來公司聯合創始人和合夥人。寒武紀生物製藥是一個新的製藥公司與一個革命性的方法來開發和管理藥物開發與年齡相關的疾病。 What we’re most interested in, though, is how Cambrian’s executive team attracts and retains top talent. (Spoiler: They give them an oversized amount of equity compared to traditional pharmaceutical companies.) James and Maryanna spoke to us about: Developing therapeutics for anti-aging in a way that works with the existing regulatory structure How James and Maryanna solve the ‘venture capital math problem’ But first we spoke on moving research from academia to the real world and fighting misconception and buzzwords around longevity biotech Who’s playing the long game in edtech? Today’s interview was led by TechCrunch Senior Reporter and edtech expert, Natasha Mascarenhas . Natasha spoke to Sam Chaudhary , the founder of ClassDojo , who spent eight years building the edtech consumer app that focuses on student classrooms, before introducing a formal revenue model. Joining Sam is his investor Chris Farmer , the founder and CEO of SignalFire , a seed-stage venture firm that recently raised $900 million across four new funds. Sam and Chris spoke to us about: How Sam played the long-game in edtech and what he’d do differently if he had to do it all over again Why SignalFire chose to navigate the edtech space, specifically the connection between kids and consumers How Chris sees investing in companies that aren’t rushing to monetize The “outsider advantage” and its tension with insider knowledge Managing uncertainty with Habi and Inspired Capital Matt Burns spoke to Brynne McNulty Rojas, who’s the co-founder and CEO of Habi, the hot real estate startup out of Colombia which reached unicorn status last year. Brynne founded Habi to bring modern home buying tools to low- and middle-class home buyers in her home country of Colombia. Now, with a valuation above $1 billion USD, Habi is a serious player in the LatAm home buying market where the majority of the homes for sale are not listed online. Joining Brynne in this conversation is Mark Batsiyan , a co-founder and partner at Inspired Capital . Brynne and Mark spoke to us about: Habi’s growth and what it was like to work with US-based investors How Brynne built her team’s confidence during a period of uncertainty The value of transparency and sharing vulnerability And advice to founders raising in today’s market AI innovation for in vitro fertilization with Root Ventures and Oma Fertility Today’s interview was led by Neesha Tambe , TechCrunch’s Startup Battlefield editor who’s also largely responsible for the hundreds of startups pitching and exhibiting at TechCrunch Disrupt. But she’s here today because of her personal experience with I-V-F. Neesha spoke with Oma Robotics o-founder Kiran Joshi and Root Ventures Partner Chrissy Meyer . Unlike many other fertility providers, Oma focuses on male infertility, and today we’re going to hear about a few things: Oma Fertility’s experience building a company in healthcare during a global pandemic How Root made the jump to virtual-first investments, which is now the new norm And how founders can craft their story and stand out in a crowded market
寒武紀生物製藥投資
4投資
寒武紀生物製藥已4投資。他們最新的投資維塔療法作為他們的一部分B係列在2022年10月10日。
寒武紀生物製藥投資活動
日期 |
輪 |
公司 |
量 |
新的嗎? |
共同投資者 |
來源 |
---|---|---|---|---|---|---|
10/12/2022 |
B係列 |
維塔療法 |
31美元 |
沒有 |
12 |
|
6/23/2021 |
一個係列 |
|||||
1/14/2021 |
B係列 |
|||||
10/8/2020 |
一個係列 |
寒武紀生物製藥投資退出
1投資退出
寒武紀生物製藥有1投資組合退出。他們最新的投資退出喚醒Biotherapeutics 在2021年2月4日,。
日期 |
退出 |
公司 |
估值
提交的估值公司,采自國家申請或者新聞,由VentureSource的提供,或基於比較數據的估值模型。
|
收購者 |
來源 |
---|---|---|---|---|---|
2/4/2021 |
首次公開募股 |
公共 |
25 |
日期 |
2/4/2021 |
---|---|
退出 |
首次公開募股 |
公司 |
|
估值 |
|
收購者 |
公共 |
來源 |
25 |
寒武紀生物製藥團隊
7團隊成員
寒武紀生物製藥有7 團隊成員,包括,。
的名字 |
工作經曆 |
標題 |
狀態 |
---|---|---|---|
基督教Angermayer |
創始人 |
當前的 |
|
的名字 |
基督教Angermayer |
||||
---|---|---|---|---|---|
工作經曆 |
|||||
標題 |
創始人 |
||||
狀態 |
當前的 |
發現正確的解決方案為您的團隊
CB見解188bet游戏科技市場情報平台分析數百萬數據點在供應商、產品、合作關係,專利來幫助您的團隊發現他們的下一個技術解決方案。